COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company ...

DF-003 is the first ALPK1 inhibitor to successfully complete a first-in-human Phase 1 study and has now entered a Phase 1b clinical trial in patients with ROSAH syndrome (NCT06395285), where it is ...

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

As biological data volume continues to grow, sequence-based AI is poised to become the dominant discovery layer across pharma, biotech, and industrial biology. Ainnocence is expanding partnerships, ...

An estimated 3 million Americans have an inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis. But ...

Siegfried, a global CDMO for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital ...

Dewpoint has selected a novel small molecule to prevent the formation of abnormal TDP-43 protein clumps in ALS and other ...

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the ...

Key market opportunities for the global small molecule healthcare contract manufacturing sector include increased demand for ...